project id: TCGA-PRAD; case submitter id: TCGA-VN-A88P; selected normal wgs: true; source center: 23; state: released; a260 a280 ratio: 1.96; normal tumor genotype snp match: Yes; ribosomal rna 28s 16s ratio: 0.99; rna integrity number: 8.1; age at index: 60; days to birth: -21916; ethnicity: not hispanic or latino; gender: male; race: white; vital status: Alive; year of birth: 1951; age at diagnosis: 21916; ajcc clinical m: M0; ajcc clinical t: T1c; ajcc pathologic n: N0; ajcc pathologic t: T2c; classification of tumor: not reported; days to diagnosis: 0; days to last follow up: 1260.0; icd 10 code: C61; last known disease status: not reported; morphology: 8140/3; primary diagnosis: Adenocarcinoma, NOS; primary gleason grade: Pattern 3; prior malignancy: no; prior treatment: No; progression or recurrence: not reported; secondary gleason grade: Pattern 4; site of resection or biopsy: Prostate gland; synchronous malignancy: No; tissue or organ of origin: Prostate gland; tumor grade: Not Reported; year of diagnosis: 2011; treatment or therapy: no; alcohol history: Not Reported; is ffpe: false; composition: Not Reported; days to collection: 911; initial weight: 140.0; sample id: 728497c3-ad8b-49e1-ac0e-9a28c48404e5; sample submitter id: TCGA-VN-A88P-01A; portion id: cee9d430-143a-45d4-8ade-af1e0aae3340; portion submitter id: TCGA-VN-A88P-01A-11; slide id: 9ce4d2c0-e657-429b-8285-cd8ce5333f75; slide submitter id: TCGA-VN-A88P-01A-01-TSA; percent lymphocyte infiltration: 0.0; percent monocyte infiltration: 0.0; percent necrosis: 0.0; percent neutrophil infiltration: 0.0; percent normal cells: 0.0; percent stromal cells: 30.0; percent tumor cells: 70.0; percent tumor nuclei: 85.0; section location: TOP;